Artelo Biosciences, Inc. Common Stock
ARTLArtelo Biosciences, Inc. is a biotechnology company focused on developing novel therapies that target the endocannabinoid system to treat various conditions, including cancer, pain, and inflammation. The company's approach involves identifying and advancing small-molecule drugs that modulate cannabinoid receptors and related pathways. Founded with an emphasis on innovative research, Artelo Biosciences aims to improve patient outcomes by leveraging the therapeutic potential of the endocannabinoid system.
Company News
Artelo Biosciences reminds shareholders to submit proxies in advance of its Annual Meeting scheduled for July 17, 2026. The company emphasizes that proxy submissions help establish quorum regardless of voting direction, and notes that failure to achieve quorum could result in meeting adjournment and additional expenses.
Artelo Biosciences completed a private placement raising $11.0 million through the sale of 3.2 million shares and warrants at $3.45 per share. The company plans to use proceeds for working capital, general corporate purposes, and bridge debt repayment. Warrants could generate an additional $20.4 million if fully exercised.
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced a public offering of 441,210 common stock shares and pre-funded warrants, expecting to raise approximately $2.0 million to support its therapeutic development efforts.
Artelo Biosciences is conducting an underwritten public offering of common stock and pre-funded warrants, with R.F. Lafferty & Co., Inc. acting as the sole book-running manager.
The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.
